Articles
Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data

https://doi.org/10.1016/S1473-3099(14)70780-7Get rights and content

Summary

Background

Antibiotic drug consumption is a major driver of antibiotic resistance. Variations in antibiotic resistance across countries are attributable, in part, to different volumes and patterns for antibiotic consumption. We aimed to assess variations in consumption to assist monitoring of the rise of resistance and development of rational-use policies and to provide a baseline for future assessment.

Methods

With use of sales data for retail and hospital pharmacies from the IMS Health MIDAS database, we reviewed trends for consumption of standard units of antibiotics between 2000 and 2010 for 71 countries. We used compound annual growth rates to assess temporal differences in consumption for each country and Fourier series and regression methods to assess seasonal differences in consumption in 63 of the countries.

Findings

Between 2000 and 2010, consumption of antibiotic drugs increased by 35% (from 52 057 163 835 standard units to 70 440 786 553). Brazil, Russia, India, China, and South Africa accounted for 76% of this increase. In most countries, antibiotic consumption varied significantly with season. There was increased consumption of carbapenems (45%) and polymixins (13%), two last-resort classes of antibiotic drugs.

Interpretation

The rise of antibiotic consumption and the increase in use of last-resort antibiotic drugs raises serious concerns for public health. Appropriate use of antibiotics in developing countries should be encouraged. However, to prevent a striking rise in resistance in low-income and middle-income countries with large populations and to preserve antibiotic efficacy worldwide, programmes that promote rational use through coordinated efforts by the international community should be a priority.

Funding

US Department of Homeland Security, Bill & Melinda Gates Foundation, US National Institutes of Health, Princeton Grand Challenges Program.

Introduction

Antibiotic drugs have reduced the burden of common infectious diseases and become essential for many medical interventions.1, 2 However, antibiotic-resistant pathogens have emerged and spread among human and animal populations worldwide.3, 4 Pathogens such as meticillin-resistant Staphylococcus aureus (MRSA)5 and carbapenem-resistant Enterobacteriaceae (CRE)6 have become a global problem. The loss of efficacy against common pathogens has not only led to a shift towards more expensive antibiotic drugs in high-income countries, but also to increased morbidity and mortality in low-income and middle-income countries, where affordability of second-line drugs restricts their use.1

The emergence of drug-resistant bacterial strains is due to the selection pressure (an external force that reduces reproductive success of some individuals in a population) imposed by use of antibiotics. The intensity of this natural event is driven by a population's volume of consumption of antibiotic drugs, whether use is appropriate or not.7, 8, 9, 10, 11 Identification of spatial and temporal trends in antibiotic consumption is important to understand the epidemiology of antibiotic resistance. First, identification of regions in which rate of consumption of antibiotics per person is high or rising can rapidly predict where the threat of new resistant infections will be greatest12 and can help to inform initiatives to preserve antibiotic efficacy.13, 14 Second, mapping of the distribution of antibiotic consumption provides a baseline for the assessment of efforts for future antibiotic drug reduction.

Although some estimates have been made, a comprehensive analysis has not been completed. In the USA, the ResistanceMap project12 mapped the distribution of use of cephalosporins, macrolides, penicillins, fluoroquinolones, tetracyclines, and trimethoprim. Goossens and colleagues8 made a detailed inventory of antibiotic use in the European Union and neighbouring countries.15 In 1987, Col and colleagues16 first attempted to estimate the global use of antibiotic drugs with data for a few countries. In this report, we aim to assess antibiotic consumption patterns from 2000 to 2010 for 16 groups of antibiotic drugs in 71 countries.

Section snippets

Methods

We used IMS Health MIDAS (IMS Health, Danbury, CT, USA) to quantify antibiotic drug consumption. With use of national sample surveys done by pharmaceutical sales distribution channels (ie, from manufacturer to wholesaler to retailer), this database estimates antibiotic consumption from the volume of antibiotics sold in retail and hospital pharmacies. In each sector, data are collected regularly to estimate direct sales from antibiotic drug manufacturers and indirect sales from wholesalers. The

Results

Between 2000 and 2010, consumption of antibiotic drugs increased by 35% (from 52 057 163 835 standard units in 2000 to 70 440 786 553 standard units in 2010). Cephalosporins and broad-spectrum penicillins accounted for 55% of the total standard units consumed in 2010 (figure 1). The largest absolute increases in consumption between 2000 and 2010 were observed for cephalosporins (8·1×109 standard units), broad-spectrum penicillins (5·8×109 standard units), and fluoroquinolones (3·0×109 standard

Discussion

This study, to our knowledge, is the first to attempt to map and compare the evolution of antibiotic consumption on a global scale since the previous review, 27 years ago;16 a period in which antibiotic use patterns could have changed greatly (panel).16 We showed that antibiotic consumption increased substantially (35% increase between 2000 and 2010), mainly in developing countries. Three quarters of this increase occurred in BRICS countries, whereas their share in the overall increase in

References (60)

  • MV Edelstein et al.

    Spread of extensively resistant VIM-2-positive ST235 Pseudomonas aeruginosa in Belarus, Kazakhstan, and Russia: a longitudinal epidemiological and clinical study

    Lancet Infect Dis

    (2013)
  • A Kotwani et al.

    Antibiotic-prescribing practices of primary care prescribers for acute diarrhea in New Delhi, India

    Value Health

    (2012)
  • TR Walsh et al.

    Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study

    Lancet Infect Dis

    (2011)
  • DJ Morgan et al.

    Non-prescription antimicrobial use worldwide: a systematic review

    Lancet Infect Dis

    (2011)
  • S Mölstad et al.

    Sustained reduction of antibiotic use and low bacterial resistance: 10-year follow-up of the Swedish Strama programme

    Lancet Infect Dis

    (2008)
  • KL O'Brien et al.

    Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates

    Lancet

    (2009)
  • J Davies et al.

    Origins and evolution of antibiotic resistance

    Microbiol Mol Biol Rev

    (2010)
  • SB Levy et al.

    Antibacterial resistance worldwide: causes, challenges and responses

    Nat Med

    (2004)
  • Antimicrobial resistance factsheet

  • P Nordmann et al.

    Global spread of carbapenemase-producing Enterobacteriaceae

    Emerg Infect Dis

    (2011)
  • R Laxminarayan et al.

    Challenges of drug resistance in the developing world

    BMJ

    (2012)
  • F Megraud et al.

    Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption

    Gut

    (2013)
  • AF Shorr

    Epidemiology of staphylococcal resistance

    Clin Infect Dis

    (2007)
  • GJ Moran et al.

    Methicillin-resistant S. aureus infections among patients in the emergency department

    N Engl J Med

    (2006)
  • Resistance Map

  • M Ferech et al.

    European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe

    J Antimicrob Chemother

    (2006)
  • NF Col et al.

    Estimating worldwide current antibiotic usage: report of Task Force 1

    Rev Infect Dis

    (1987)
  • Population estimates and projections

  • APW Team

    Antimicrobial stewardship: what's it all about? Australian Prescriber

  • Antimicrobial stewardship in Australian Hospitals 2011

  • Cited by (1638)

    View all citing articles on Scopus
    View full text